Melville, NY – October 15, 2003 – Fougera^® announced the shipment of 2,836 vials (1,418 cartons) of its snakebite antivenom CroFab™ (Crotalidae Polyvalent Immune Fab -- Ovine). Year to date Fougera has shipped 31,370 vials (15,685 cartons) of CroFab. In 2002 Fougera shipped 16,180 vials (8,090 cartons) of CroFab. Hospitals and poison control centers are encouraged to stock adequate supplies of CroFab for the Fall 2003 and Spring 2004 snakebite seasons. The shelf life of CroFab is 30 months.

“Year to date 2003 we have already come close to doubling our the number of vials of CroFab^TM we shipped in 2002. We are optimistic that more shipments of CroFab will become available in 2003 and production levels will keep pace in 2004,” said David Klaum, Vice President Sales and Marketing, Fougera.

CroFab™ is indicated for the management of patients with minimal or moderate North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly know as the Crotalidae) of venomous snakes that includes rattlesnakes, copperheads and cottonmouths/water moccasins. In October 2002, Fougera^® assumed responsibility for the distribution of CroFab from Savage Laboratories. Both companies are divisions of Altana Inc. CroFab was developed and is manufactured by Protherics PLC. Complete prescribing information is available at www.fougera.com.

“In most regions of the country Fall and Spring are the peak snakebite seasons. Broad availability and stocking of antivenom is very important,” said Richard C. Dart, MD, PhD, Director, Rocky Mountain Poison and Drug Center, Denver Health Authority and Professor of Medicine, Surgery and Pharmacy, University of Colorado Health Sciences Center.

Of the estimated 45,000 snakebites each year in the United States, approximately 7,000 to 8,000 involve venomous species. Additional information about snakebites and snakebite treatments can be found at www.snakebitenews.com.

- ### -

About Fougera^®
Fougera is a leading manufacturer and distributor of a wide range of multi-source topical and ophthalmic pharmaceuticals in prescription and over-the-counter dosage forms, as well as treatments for emergency/critical care.